Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 8/20 | 0.64 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.64 |
| ▸ | ITGA4 | P13612 | 9/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ITGAV | P06756 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709333 | 0.92 | ITGB1 (0.54) | ITGB1ITGA5ITGA4RAB9AITGAV | |
| SCHEMBL6714274 | 0.90 | ITGB1 (0.65) | ITGB1ITGA5ITGA4ITGAVALDH1A1 | |
| SCHEMBL3850475 | 0.87 | ITGA4 (0.64) | ITGB1ITGA5ITGA4RAB9AALDH1A1 | |
| SCHEMBL27687381 | 0.87 | ITGA4 (0.64) | ITGB1ITGA5ITGA4RAB9AALDH1A1 | |
| SCHEMBL5690742 | 0.87 | ITGB1 (0.71) | ITGB1ITGA5ITGA4ITGAVALDH1A1 | |
| SCHEMBL6712264 | 0.87 | ITGB1 (0.57) | ITGB1ITGA5ITGA4RAB9AITGAV | |
| SCHEMBL6709558 | 0.85 | ITGB1 (0.69) | ITGB1ITGA5ITGA4ITGAVALDH1A1 | |
| SCHEMBL7066469 | 0.85 | ALDH1A1 (0.70) | ITGB1ITGA5ITGA4RAB9AITGAV | |
| SCHEMBL7069740 | 0.85 | ALDH1A1 (0.70) | ITGB1ITGA5ITGA4RAB9AITGAV | |
| SCHEMBL27514023 | 0.85 | ALDH1A1 (0.70) | ITGB1ITGA5ITGA4RAB9AITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-08 | — | — | US | claimed |
| US-6583139-B1 | Treatment of inflammatory diseases; inflammatory brain diseases such as multiple sclerosis; N-(Toluene-4-sulfonyl)-L-prolyl-4-(alpha -methylbenzyloxy)-L-phenylalanine; Very Late Antigen 4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-06-24 | — | — | US | claimed |
| EP-0994896-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1999006437-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS INC. (US) | 1999-02-11 | — | — | WO | claimed |
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-08 | — | — | US | disclosed |
| US-6583139-B1 | Treatment of inflammatory diseases; inflammatory brain diseases such as multiple sclerosis; N-(Toluene-4-sulfonyl)-L-prolyl-4-(alpha -methylbenzyloxy)-L-phenylalanine; Very Late Antigen 4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-06-24 | — | — | US | disclosed |
| EP-0994896-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999006437-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | ITGB1 32/4885ITGA5 85/4885ITGA4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.